Do non-selective beta-blockers reduce Tpeak/end compared to cardio-selective beta-blockers in patients with long QT syndrome type 1?
Tpeak/end may serve as a novel ECG marker for beta-blocker efficacy in LQT1, with non-selective beta-blockers showing a marked reduction compared to cardio-selective agents.
•Non-selective β-blockers markedly reduce Tpeak/end in LQT1 patients.•Cardio-selective β-blockers show no consistent effect on Tpeak/end.•The nsBB effect persists after exercise, independent of heart rate.•Tpeak/end shortening indicates decreased global repolarization heterogeneity and reduced arrhythmic risk.•Tpeak/end may serve as a novel ECG marker for β-blocker efficacy in LQT1.
Rieder et al. (2026) studied this question.